QYUNS-B

02509
14.6001.39% ( +0.200 )
Delay Closed: Nov 17, 16:08:15

Profile

About

QYUNS-B
QYUNS-B
02509.HK

Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, engages in the research and development of biologic therapies for autoimmune and allergic diseases in China. Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor, which completed Phase III clinical trial for the treatment of ankylosing spondylitis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra that is in Phase III clinical trial for treating prurigo nodularis. The company also develops QX001S, which is an IL-12/L-23p40 inhibitor for psoriasis under the SAILEXIN brand. In addition, the company develops QX008N, a humanized IgG1 mAb targeting thymic stromal lymphopoietin that is in Phase Ib clinical trial to treat moderate-to-severe asthma and chronic obstructive pulmonary disease; and QX004N, an IL-23p19 inhibitor, which is in Phase II clinical trial to treat psoriasis and Crohn’s disease.

Profile

Company Name
Qyuns Therapeutics Co., Ltd.
Market
SEHK
Founded
Industry
--
Fiscal Year End
December 31

Related Securities

Industry

Management